Clinicians report potential lithium toxicity in patients switching GLP-1 agents, indicating the need for careful monitoring.
Clinicians should be vigilant when initiating or switching GLP-1-modulating agents in patients receiving lithium. Pharmacokinetic studies are needed to clarify the mechanism of this interaction. Until more is known, increased monitoring of lithium levels is warranted, with initiation of a GLP-1-modulating agent, a dose change, or switching to another agent.
No takes yet. Share an insight, caveat, or question.
Burson et al. (2026) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: